1145 related articles for article (PubMed ID: 32966830)
1. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
2. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
[TBL] [Abstract][Full Text] [Related]
3. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Pusztai L; Denkert C; O'Shaughnessy J; Cortes J; Dent R; McArthur H; Kümmel S; Bergh J; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Zhu Y; Pan W; Tryfonidis K; Schmid P
Ann Oncol; 2024 May; 35(5):429-436. PubMed ID: 38369015
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Phua LC; Lee SC; Ng K; Abdul Aziz MI
BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Cescon DW; Schmid P; Rugo HS; Im SA; Md Yusof M; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Haiderali A; Zhou X; Guo Z; Nguyen AM; Cortes J
J Natl Cancer Inst; 2024 May; 116(5):717-727. PubMed ID: 38070159
[TBL] [Abstract][Full Text] [Related]
6. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
Dent R; André F; Gonçalves A; Martin M; Schmid P; Schütz F; Kümmel S; Swain SM; Bilici A; Loirat D; Villalobos Valencia R; Im SA; Park YH; De Laurentis M; Colleoni M; Guarneri V; Bianchini G; Li H; Kirchmayer Machackova Z; Mouta J; Deurloo R; Gan X; Fan M; Mani A; Swat A; Cortés J
Ann Oncol; 2024 May; ():. PubMed ID: 38755096
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
Liang Y; Liu J; Ge J; Shi Q; Zhang G; Wan A; Luo T; Tian H; Fan L; Wang S; Chen L; Tang P; Zhu K; Jiang J; Bian X; Zhang Y; Qi X
EClinicalMedicine; 2024 May; 71():102585. PubMed ID: 38638401
[TBL] [Abstract][Full Text] [Related]
9. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H; Liberman M; Kato T; Tsuboi M; Lee SH; Gao S; Chen KN; Dooms C; Majem M; Eigendorff E; Martinengo GL; Bylicki O; Rodríguez-Abreu D; Chaft JE; Novello S; Yang J; Keller SM; Samkari A; Spicer JD;
N Engl J Med; 2023 Aug; 389(6):491-503. PubMed ID: 37272513
[TBL] [Abstract][Full Text] [Related]
10. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Mutai R; Kuchuk I; Goldshtein A; Yerushalmi R; Rotem O; Maisel Lotan A; Bdolah-Abram T; Gabizon A; Goldvaser H
Breast Cancer Res Treat; 2024 Jun; 205(2):241-248. PubMed ID: 38345692
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL; van de Haar J; van den Berg JG; van Sandick JW; Kodach LL; van Dieren JM; Balduzzi S; Grootscholten C; IJsselsteijn ME; Veenhof AAFA; Hartemink KJ; Vollebergh MA; Jurdi A; Sharma S; Spickard E; Owers EC; Bartels-Rutten A; den Hartog P; de Miranda NFCC; van Leerdam ME; Haanen JBAG; Schumacher TN; Voest EE; Chalabi M
Nat Med; 2024 Feb; 30(2):519-530. PubMed ID: 38191613
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Fountzila E; Ignatiadis M
Ecancermedicalscience; 2020; 14():1147. PubMed ID: 33574892
[TBL] [Abstract][Full Text] [Related]
14. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid P; Turner NC; Barrios CH; Isakoff SJ; Kim SB; Sablin MP; Saji S; Savas P; Vidal GA; Oliveira M; O'Shaughnessy J; Italiano A; Espinosa E; Boni V; White S; Rojas B; Freitas-Junior R; Chae Y; Bondarenko I; Lee J; Torres Mattos C; Martinez Rodriguez JL; Lam LH; Jones S; Reilly SJ; Huang X; Shah K; Dent R
Clin Cancer Res; 2024 Feb; 30(4):767-778. PubMed ID: 38060199
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Zong Y; Wu J; Shen K
Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
[TBL] [Abstract][Full Text] [Related]
16. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study.
Zheng C; Liu Y; Wang X; Bi Z; Qiu P; Qiao G; Bi X; Shi Z; Zhang Z; Chen P; Sun X; Wang C; Zhu S; Meng X; Song Y; Qi Y; Li L; Luo N; Wang Y
Int J Surg; 2024 Mar; 110(3):1527-1536. PubMed ID: 38116673
[TBL] [Abstract][Full Text] [Related]
18. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
Wu D; Li Y; Xu P; Fang Q; Cao F; Lin H; Li Y; Su Y; Lu L; Chen L; Li Y; Zhao Z; Hong X; Li G; Tian Y; Sun J; Yan H; Fan Y; Zhang X; Li Z; Liu X
Nat Commun; 2024 Mar; 15(1):2177. PubMed ID: 38467604
[TBL] [Abstract][Full Text] [Related]
20. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
Musher BL; Rowinsky EK; Smaglo BG; Abidi W; Othman M; Patel K; Jawaid S; Jing J; Brisco A; Leen AM; Wu M; Sandin LC; Wenthe J; Eriksson E; Ullenhag GJ; Grilley B; Leja-Jarblad J; Hilsenbeck SG; Brenner MK; Loskog ASI
Lancet Oncol; 2024 Apr; 25(4):488-500. PubMed ID: 38547893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
